Get the Stockscreener App
0.005
9,900%
0.0045
Vaxxinity Inc stock is traded at $0.005, with a volume of 100.
It is up +9,900% in the last 24 hours and down -87.90% over the past month.
See More
Previous Close:
$0.0005
Open:
$0.005
24h Volume:
100
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-66.00M
P/E Ratio:
-0.00943
EPS:
-0.53
Net Cash Flow:
$-60.55M
1W Performance:
+9,900%
1M Performance:
-87.90%
6M Performance:
-95.00%
1Y Performance:
-97.29%
1-Day Range:
$0.005
$0.005
1-Week Range:
$0.005
$0.005
52-Week Range:
$0.005
$0.005
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.005 | 0 | 0 | -66.00M | -60.55M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-23 | Initiated | Robert W. Baird | Outperform |
| Apr-27-22 | Initiated | Evercore ISI | In-line |
Vaxxinity Inc Stock (VAXX) Latest News
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - MSN
Comparing Dynavax Technologies (NASDAQ:DVAX) & Vaxxinity (NASDAQ:VAXX) - Defense World
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
IPO Roundup: Guardian Pharmacy Services, BKV Corp and more (NYSEARCA:IPO) - Seeking Alpha
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Victory Capital Management Inc. Makes New Investment in MediaAlpha, Inc. (NYSE:MAX) - Defense World
Zhengye Biotechnology Holding Limited Plans $7 Million IPO for September 27th (ZYBT) - Defense World
Victory Capital Management Inc. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Broker tips: Volution, UK supermarkets - ShareCast
Vaxcyte president and CFO sells over $900k in stock - Investing.com
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech - MSN
Waltham biotech joins IPO buzz, plans to list on Nasdaq - The Business Journals
Vaxxinity - The Pharma Letter
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - GlobeNewswire
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
Vaxxinity (VAXX) Stock Forecast and Price Target 2024 - MarketBeat
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases - Yahoo Finance
Could space travel research deliver a frailty vaccine? - Longevity.Technology
Vaxxinity, UCF to develop special new vaccines for deep-space astronauts - The Business Journals
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - GlobeNewswire
Vaxxinity making vaccines to change the world - Labiotech.eu
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Vax-Before-Travel
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease - Yahoo Finance
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - South Florida Hospital News
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease - Yahoo Finance
VXX-301, a tau vaccine with optimized properties - BioWorld Online
Vaxxinity to Present at World Vaccine Congress, American - GlobeNewswire
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment - Fierce Biotech
Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology
Vaxxinity Joins TransCelerate Research and Development Consortium - Yahoo Finance
Vaxxinity Announces First Subjects Dosed in Phase 1 - GlobeNewswire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences - GlobeNewswire
Vaxxinity moves HQ, jobs to Florida's Space Coast from Texas - The Business Journals
Vaxxinity Inc Stock (VAXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Cap:
|
Volume (24h):